# OnCo record paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017" ;
  schema:name "Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial"@en ;
  schema:description "Adding the AKT inhibitor ipatasertib to first-line paclitaxel lengthened the time before metastatic triple-negative cancer grew from 4.9 to 6.2 months, the first randomised support for AKT-directed therapy in the disease."@en ;
  schema:url <https://onco.cc/key-papers/paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(17)30450-3>, <https://pubmed.ncbi.nlm.nih.gov/28800861/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(17)30450-3> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Kim SB, Dent R, Im SA, et al." ;
  onco:related <https://onco.cc/biomarkers/pten-alteration/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:targets <https://onco.cc/targets/akt/>, <https://onco.cc/targets/pten/> ;
  onco:drugs <https://onco.cc/drugs/ipatasertib/>, <https://onco.cc/drugs/paclitaxel/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:people <https://onco.cc/people/kim-sung-bae/>, <https://onco.cc/people/rebecca-dent/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .